Lexeo rises as it announces leadership changes
27/01/2026 13:31
** Shares of drug developer Lexeo Therapeutics LXEO.O rise 2% to $7.63 premarket ** Co says it named cardiologist Dr. Narinder Bhalla as chief medical officer ** Co says its research head Dr. Eric Adler will become CEO of Myoventive, which focuses on RNA-based treatments for inherited heart conditions ** CTO José Manuel Otero moves to the chief operating officer's role; co also hires two VPs to lead early- and late-stage cardiology programs - LXEO ** Shares up ~51% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease